Abstract The Anxiety Disorders Association of America convened a conference of experts to
address treatment‐resistant anxiety disorders and review promising novel approaches to the …

Modern pharmacological treatments for anxiety disorders are safer and more tolerable than
they were 30 years ago. Unfortunately, treatment efficacy and duration have not improved in …

Anxiety disorders affect one-eighth of the total population worldwide, and have become a
very important area of research interest in psychopharmacology. People with anxiety …

Given the enormous contribution of anxiety disorders to the burden of disease, it is key to
optimize their prevention and treatment. In this critical review we assess advances in the …

Rapid developments in recent years in basic science and pharmacology has greatly
increased understanding of the causes of anxiety disorders. This has led to a large number …

Anxiety disorders, including panic disorder/agoraphobia (PDA), generalized anxiety
disorder (GAD), social anxiety disorder (SAD), and others, are the most prevalent mental …

This review has attempted to highlight the recent advances in our knowledge of the
psychopharmacological treatment of anxiety disorders. Overall, substantial advances have …

Anxiety disorders, as a group, are among the most common mental health conditions and
frequently cause significant functional impairment. Both psychotherapeutic and …

Anxiety disorders are the most prevalent psychiatric disorders and a leading cause of
disability. While there continues to be expansive research in posttraumatic stress disorder …

This article reviews the evidence from randomized, placebo‐controlled trials and meta‐
analyses of pharmacological treatments of the following anxiety disorders: generalized …